Ownership and insider activity for Medpace Holdings, Inc. (MEDP): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance.
Price
| Price | $648.14 (closing price, November 2, 2026) |
| Market Cap | $18.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-26 | BURWIG SUSAN E | M-Exempt | 328 | $55K |
| 2026-10-26 | BURWIG SUSAN E | S-Sale | 16,060 | $10.9M |
| 2026-10-27 | BURWIG SUSAN E | S-Sale | 3,940 | $2.7M |
| 2026-10-26 | BURWIG SUSAN E | M-Exempt | 328 | $55K |
| 2026-10-21 | BURWIG SUSAN E | M-Exempt | 2,700 | $450K |
| 2026-10-21 | BURWIG SUSAN E | M-Exempt | 2,700 | $450K |
| 2026-10-12 | BURWIG SUSAN E | M-Exempt | 3,000 | $500K |
| 2026-10-12 | BURWIG SUSAN E | M-Exempt | 3,000 | $500K |
| 2026-10-07 | BURWIG SUSAN E | M-Exempt | 2,000 | $333K |
| 2026-10-07 | BURWIG SUSAN E | M-Exempt | 2,000 | $333K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.1M | $26.5M | $23.3M | $131.9M | $277.8M | $461.3M | $28.3M | $245.4M | $669.4M | $497.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $79.8M | $83.1M | $133.4M | $155.7M | $161.0M | $186.4M | $253.4M | $298.4M | $296.4M | $402.1M |
| Inventory | $308,000 | $7,000 | $7,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $133.2M | $130.0M | $178.1M | $317.0M | $473.7M | $690.9M | $334.0M | $593.8M | $1.03B | $989.6M |
| Property, Plant & Equipment | $43.8M | $48.7M | $52.3M | $99.4M | $198.8M | $222.7M | $248.9M | $265.4M | $252.3M | $248.9M |
| Goodwill | $661.0M | $661.0M | $661.0M | $662.4M | $662.4M | $662.4M | $662.4M | $662.4M | $662.4M | $662.4M |
| Intangible Assets | $136.1M | $98.7M | $69.2M | $54.4M | $46.5M | $41.4M | $38.0M | $35.8M | $34.4M | $33.4M |
| Total Assets | $979.1M | $950.7M | $967.9M | $1.14B | $1.39B | $1.66B | $1.35B | $1.66B | $2.10B | $1.98B |
| Accounts Payable | $10.9M | $16.7M | $16.7M | $22.4M | $26.6M | $25.7M | $33.1M | $31.9M | $32.5M | $28.1M |
| Short-term Debt | $12.4M | $16.5M | 0 | 0 | 0 | 0 | $50.0M | 0 | 0 | 0 |
| Total Current Liabilities | $168.6M | $192.7M | $257.0M | $343.0M | $440.1M | $557.2M | $803.5M | $925.1M | $1.10B | $1.34B |
| Long-term Debt | $151.3M | $205.1M | $79.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $368.4M | $447.2M | $378.2M | $416.8M | $584.9M | $707.0M | $966.1M | $1.10B | $1.28B | $1.52B |
| Retained Earnings | -$9.6M | -$120.4M | -$41.5M | $68.1M | $115.2M | $235.0M | -$359.8M | -$221.6M | $8.2M | -$460.0M |
| Total Equity | $610.7M | $503.5M | $589.7M | $726.3M | $805.8M | $952.9M | $386.4M | $559.0M | $825.5M | $459.1M |
| Total Debt | $163.6M | $223.5M | $81.8M | $56.2M | $131.0M | $147.2M | $208.1M | $164.5M | $149.5M | $136.9M |
| Net Debt | $126.5M | $197.0M | $58.5M | -$75.7M | -$146.7M | -$314.1M | $179.9M | -$81.0M | -$519.9M | -$360.2M |
| Working Capital | -$35.4M | -$62.7M | -$78.9M | -$26.0M | $33.5M | $133.7M | -$469.5M | -$331.3M | -$75.3M | -$354.1M |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 0.83 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 8.04 |
Profitability
| Return on Equity | 99.76% |
| Return on Invested Capital | 62.17% |
| Return on Assets | 22.49% |
| Gross Margin | 29.14% |
| Operating Margin | 21.39% |
| Net Margin | 18.24% |
Related companies: ICLR · IQV · CRL · TMO · 0R0H.L · DHR · 0R2B.L · NTRA
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MEDP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks